Ozempic
Type 2 diabetes drug
Once-weekly semaglutide injection for adults with type 2 diabetes, Novo Nordisk's best-selling medicine worldwide.
Type 2 diabetes drugSince 2017
How it started
Novo's own semaglutide, approved 2017.
2017the year it started
Novo Nordisk developed semaglutide in-house and won US FDA approval for Ozempic in December 2017 after the SUSTAIN trial programme.
How big it is
How big is Ozempic?
DKK 127.1BOzempic salesFY2025
Its place in Novo Nordisk
Four in ten Novo Nordisk kroner.
41.1%of Novo Nordisk salesFY2025
Ozempic is the core of Novo's Diabetes care business and its largest single product.
Who it competes with
MMounjaro (Lilly)TTrulicity (Lilly)JJardiance
What Novo Nordisk does not disclose
- Ozempic operating profit
- Number of people treated with Ozempic
- Ozempic sales split by region in the product table
- Net price per prescription
The group behind itNovo Nordisk
→
Sources
Every number on this page comes from Novo Nordisk's own reports.
Point your phone at a logo.
See the company behind it.
The full story in 12 chapters · compare any two companies · 335 companies, and any other on request.
Download on the App Store
